Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian...

Area of Science:

• Gynecologic Oncology
• Clinical Cancer Research
• Epidemiology

Background:

• Epithelial ovarian cancer (EOC) staging is critical for prognosis and treatment planning.
• Understanding survival differences between Stage IIIA and IIIC EOC is essential for optimizing patient outcomes.

Purpose of the Study:

• To quantify the survival advantage associated with earlier detection of epithelial ovarian cancer, specifically comparing Stage IIIA to Stage IIIC.
• To evaluate treatment outcomes and survival rates in patients with Stage IIIA versus Stage IIIC EOC.

Main Methods:

• Retrospective analysis of patients with Stage IIIA and IIIC EOC treated between 2000-2009.
• Data collected from the University of Kentucky Markey Cancer Center (UKMCC) and Surveillance, Epidemiology, and End Results (SEER) institutions.
• Evaluation of treatment modalities including surgical cytoreduction and platinum-based chemotherapy.

Main Results:

• Patients with Stage IIIA EOC showed higher rates of cytoreduction to no visible disease and complete chemotherapy response compared to Stage IIIC.
• Time to progression was significantly shorter for Stage IIIC (17 months) than Stage IIIA (36 months) EOC.
• Five-year overall survival improved by approximately 19% for Stage IIIA (60% at UKMCC, 56% at SEER) compared to Stage IIIC (41% at UKMCC, 37% at SEER).
• Higher rates of no evidence of disease (NED) at last follow-up were observed in Stage IIIA (53%) versus Stage IIIC (14%) patients.

Conclusions:

• Early detection of epithelial ovarian cancer, downstaging from IIIC to IIIA, confers a substantial survival advantage.
• Surgical tumor cytoreduction and platinum-based chemotherapy are key components in achieving improved survival for earlier-stage EOC.
• The findings underscore the importance of accurate staging and timely intervention in managing epithelial ovarian cancer.